Roche entered into a definitive merger agreement to acquire Carmot Therapeutics, Inc., a privately owned company based in Berkeley, CA with a portfolio that includes clinical stage subcutaneous and oral incretins with potential to treat obesity, as well as a number of preclinical programs.   Roche will pay $2.7 billion in cash at closing and up to $400 million depending on the achievement of certain milestones. Carmot and its employees will join the Roche Group as part of Roche’s Pharmaceutica...